← Oncology Approval Tracker

FDA DECISION ·

Gavreto

pralsetinib · Blueprint Medicines

Accelerated approvalNew or expanded indicationRET fusion-positive thyroid cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults and children ages 12 years and older with advanced or metastatic RET fusion-positive thyroid cancer requiring systemic therapy that was refractory to radioactive iodine when radioactive iodine was appropriate.

LAMPGEN ANALYSIS

Why it matters

Expanded pralsetinib to a RET fusion-positive thyroid cancer population under accelerated approval.

What research teams should watch

Confirm fusion status and document prior or unsuitable radioactive iodine before applying the historical label.

PRIMARY RECORDS

Sources